InsiderSignal.AI

InsiderSignal.ai

NMRA - Neumora Therapeutics, Inc.

Insider Purchase by Arch Venture Partners Xii, LLC (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Arch Venture Partners Xii, LLC, serving as 10% owner at Neumora Therapeutics, Inc. (NMRA), purchased 1,915,700 shares at $2.61 per share, for a total transaction value of $4,999,977.00. Following this transaction, Arch Venture Partners Xii, LLC now holds 33,847,838 shares of NMRA.

This purchase represents a 6.00% increase in Arch Venture Partners Xii, LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, October 27, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, October 29, 2025, 2 days after the trade was made.

Neumora Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Arch Venture Partners Xii, LLC

10%

Arch Venture Partners XII, LLC is a Delaware-incorporated limited liability company (CIK: 0001979548) serving as the general partner of ARCH Venture Partners XII, L.P., the investment vehicle associated with ARCH Venture Fund's XII, which closed at $2.975 billion in June 2022 to fund early-stage biotechnology companies focused on breakthrough technologies in areas like neurology, oncology, and mental health.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)[[5]](https://www.sec.gov/Archives/edgar/data/2040807/000095017025011345/0000950170-25-011345-index.htm)[[7]](https://www.archventure.com/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies/) As a corporate insider and 10% owner of Neumora Therapeutics, Inc. (NMRA), it has engaged in recent trading activities related to the company's shares.[[2]](https://www.gurufocus.com/insider/235757/arch-venture-partners-xii,-l.p.)[[8]](https://www.nasdaq.com/market-activity/insiders/arch-venture-partners-xii-llc-1270763) Arch Venture Partners XII, LLC operates within the broader ARCH Venture Partners ecosystem, a Chicago-based venture capital firm founded in 1986, renowned for co-founding and investing in over 130 active early-stage companies in life sciences, biotechnology, and deep-tech from top research institutions.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[3]](https://www.archventure.com) The firm, with assets under management exceeding $10 billion, is led by managing directors including Keith Crandell, who signs on behalf of the entity, alongside co-founders Robert Nelsen and Kristina Burow.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)[[6]](https://www.sec.gov/Archives/edgar/data/1906837/000107261323000508/arch-sch13d_18764.htm) ARCH emphasizes partnering with scientists to commercialize disruptive science, providing not just capital but operational support in company building and leadership assembly.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)

View full insider profile →

Trade Price

$2.61

Quantity

1,915,700

Total Value

$4,999,977.00

Shares Owned

33,847,838

Trade Date

Monday, October 27, 2025

117 days ago

SEC Filing Date

Wednesday, October 29, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Neumora Therapeutics, Inc.

Company Overview

No company information available
View news mentioning NMRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/979221

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime